What Are the Uses of Imipenem and Cilastatin?

Imipenem is a new type of -lactam antibiotic, which has both strong broad-spectrum antibacterial activity and -lactamase inhibitory effect.

Imipenem-cilastatin sodium

Imipenem is a new type of -lactam antibiotic, which has both strong broad-spectrum antibacterial activity and -lactamase inhibitory effect.

Drug Name

Imipenem-cilastatin sodium

Alias

Slatin sodium

Foreign name

Imipenem and Cilastatin Sodium

Category

New -lactam antibiotics

Imithiomycin / cilastatin sodium, Taineng, Taining

[Foreign name] IM / CI, IMP / CS, MSD, TIENAM, PRIMAXIN

Imipenem structural formula

This product has the first-generation cephalosporin's powerful anti-gram-positive bacteria, and the third-generation cephalosporin has a high stability against the broad-spectrum -lactamase produced by negative bacilli, including negative bacilli, including Drug-resistant negative bacilli have strong antibacterial activity and are easily resistant to -lactam antibiotics. Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus faecalis, and Bacteroides fragile are also highly sensitive to this product. The antibacterial spectrum of this product includes almost all clinically significant pathogenic bacteria. Partial methicillin-resistant Staphylococcus aureus, group D streptococci are sensitive to imipenem. Cilastatin has no antibacterial effect, but it can inhibit the dehydropeptidase secreted by kidney cells in the body, protecting imipenem from hydrolysis. For infections caused by various sensitive bacteria.

Suitable for mixed infections caused by multiple pathogens and aerobic / anaerobic bacteria, as well as early treatment before pathogens are identified. For the following infections caused by sensitive bacteria:

Intraabdominal infection Lower respiratory infection Gynecological infection Septicemia Urogenital infection Bone and joint infection Skin and soft tissue infection Severe endocarditis

Patients with pulmonary or blood infections, patients with unknown pathogens (such as ICU patients), patients with high resistance to pathogenic bacteria (referring to hospitalization for more than 5-7 days), and patients who have received antibiotic treatment for other reasons.

The clinical effectiveness of imipenem and cilastatin sodium in the treatment of severe lower respiratory tract infections is 93.0% ; the total effective rate of severe infections in patients with cancer is 75.41%; Acinetobacter, Enterococcus and Citrobacter freundii are still very sensitive .

Intravenous infusion: Mild infection: 250 mg twice daily. Moderate infection: 500 1000mg once, once a day. Severe infection: 1000mg, 3 to 4 times a day.

Adverse reactions are rare, but can occur: gastrointestinal reactions, nausea, vomiting, pseudomembranous enteritis. Skin allergic reactions, rashes, itching may increase eosinophils. Occasionally white blood cells are reduced, platelets are reduced or increased, hemoglobin is decreased, and Coomb's test is positive. Renal and liver damage.

Those who are allergic to any of the ingredients in this product are prohibited. -lactam antibiotics should be used with caution.

Injection: Each bottle contains imipenem 500mg + cilasta 500mg or each bottle contains imipenem 250mg + cilasta 250mg